VEON Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
VEON is not a strong buy for a beginner, long-term investor at this moment. While the stock has some positive catalysts, the financial performance and technical indicators suggest caution. The stock is overbought with a high RSI, and the pre-market price is declining. Additionally, the company's recent financials show a significant drop in net income and EPS, which raises concerns about profitability. For a long-term investor, it would be better to wait for clearer signs of financial stability and a better entry point.
The MACD histogram is positive and expanding, indicating bullish momentum. However, the RSI of 81.366 suggests the stock is overbought. The pre-market price is down 1.98%, and the stock is trading near resistance levels (R1: 53.964, R2: 55.989), which could limit further upside in the short term.
The Competition Commission of Pakistan approved VEON's acquisition of TPL Insurance, which could enhance its digital financial services. Analysts have given a Buy rating with a $74 price target, highlighting the company's undervalued assets.
The company's Q4 2025 financials show a significant drop in net income (-138.27% YoY) and EPS (-140.00% YoY), raising concerns about profitability. The pre-market price is also declining, and the stock is overbought based on RSI.
In Q4 2025, revenue increased by 17.33% YoY to $1.171 billion, but net income dropped to -$31 million, down 138.27% YoY. EPS also dropped to -0.02, down 140% YoY. Gross margin improved slightly to 68.92%, up 0.55% YoY.
Rothschild & Co Redburn analyst Max Findlay initiated coverage with a Buy rating and a $74 price target, citing undervalued assets and a steep sum-of-the-parts discount.
